Moderna price target raised to $30 from $28 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $30 from $28 and keeps an Equal Weight rating on the shares. Following the Q4 report and reiteration that 2026 revenue would increase by up to 10% year-over-year, the jury trial outcome in March, the INT cancer program Phase 3 adjuvant melanoma data due in Q2 or Q3, and further visibility on the refusal-to-file letter for the flu vaccine represent the next key catalysts, the analyst tells investors.